Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its second quarter 2020 revenues were up 23 percent year over year.

The liquid biopsy and cancer early detection firm reported total revenues of $66.3 million for the quarter ended June 30 compared to $54.0 million in the same period of 2019, beating the $59.2 million that Wall Street had predicted on average.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.